Released September, 2019

Enhance drug discovery
with genomics data

2010 – 2019 © GeneXplain GmbH

Genome Enhancer pipelines carry out  a fully automatic analysis for patient’s multi-omics data analysis included genomics, transcriptomics, proteomics, epigenomics and metabolomics.

Once the analysis is finished, you will receive a comprehensive HTML report constructed in a form of a publication draft. The report will include detailed information about the methods used and the results obtained, including genes that characterize the studied pathology, the transcription factors that regulate those genes, and the reconstructed model of the intracellular signaling network with identified master regulators – the potential drug targets for treating the studied pathology. 

2010 – 2019 © GeneXplain GmbH

Genome Enhancer Report

2010 – 2019 © GeneXplain GmbH


Multi-omics analysis

One time analysis allows you to get the integrated reliable results data of genomics, transcriptomics, metabolomics, proteomics. 


Personalized medicine

You are able to propose therapy and identify activated drug targets by analysis processes using omics data of specific patients.


Drug target identification

Genome Enhancer reconstructs complicated signal pathway networks that identify main regulators and activate in pathology.


Easy interface

Doctors and biologists can use Genome Enhancer without basic Bioinformatics knowledge because of  complete  automatic analysis functions.


Strong scientific base

 We provide highly accuracy of disease molecular mechanism through pathway reconstruction and integration of promotors  and enhancers.



Flexible pricing

License policy of short term access allows economical use.


2010 – 2019 © GeneXplain GmbH

Main Features

  • A clear result, issued as a scientific paper
  • Suitable for use by medical doctors and biologists
  • Does not require special skills
  • Processes all types of omics data
  • Easy data upload and annotation
  • One-click run
  • Generates a report on the identified drug targets and prospective therapies

2010 – 2019 © GeneXplain GmbH